Qiagen N.V.
QGENHealthcareNASDAQDiagnostics & Research · Last scanned Sep 9, 2026
Scan Results
Daily timeframeQiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. At a $8.75B market cap, Qiagen N.V. ranks as a mid-cap company within healthcare. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories.
Market Cap
$8.75B
Beta
0.63
P/E (TTM)
21.51
P/E (Fwd)
16.24
EPS (TTM)
$1.97
EPS (Fwd)
$2.61
ROE
11.9%
ROA
5.9%
Cash
$793.5M
Total Debt
$1.65B
Free CF
$372.9M
52W Change
-5.5%
Annual Financials
Cash vs Debt
Where QGEN stands vs its 150-day and 200-day moving averages
As of the August 27, 2026 close, QGEN finished 5.12% above its 150-day moving average ($41.25) and 2.17% above its 200-day moving average ($42.44). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is QGEN overbought or oversold?
At the August 27, 2026 close, QGEN's RSI(14) was 56.4, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Qiagen N.V. carries $1.65B in total debt against $793.5M in cash reserves — debt is roughly 2.1x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow comes in at $372.9M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 11.9% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 5.9% suggests reasonable efficiency in deploying the company's asset base. Revenue has been relatively flat, moving from $2.14B (2022) to $2.09B (2025).
With a beta below 0.7, Qiagen N.V. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Qiagen N.V.'s trajectory.